Efficacy and safety of cagrilintide 2.4 mg in adults with overweight obesity: Data from REDEFINE 1 Seven Clinical Trials on Obesity Weight Loss Anticipated to Complete Soon Guideline Central GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Nature Reviews Gastroenterology & Hepatology Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet